TADC-derived RESISTIN promoted epithelial mesenchymal transformation (EMT) in lung cancer, which is a well-known mechanism underlying chemoresistance development by activating the Wolf–Hirschhorn syndrome candidate 1/Twist pathway [64]. The gene discussed is TWIST1; the disease is lung cancer.